Comparison

VEGI, Human European Partner

Item no. Z02198-50
Manufacturer GenScript
Amount 50 ug
Category
Type Proteins
Specific against Human (Homo sapiens)
Purity The purity of GenScript Recombinant Human VEGI-192 is greater than 95.0%, as determined by the following methods: (a) RP-HPLC analysis (b) Reducing and non-reducing SDS-PAGE silver-stained gel analysis
Sequence The sequence of the first five N-terminal amino acids has been found to be Met-Gln-Leu-Thr-Lys.
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias protein/Z02198-Vascular_Endothelial_Growth_Inhibitor_VEGI_human, Vascular endothelial growth inhibitor (VEGI, TNFSF-15) is a new member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli, and programmed death of proliferating cells. These activities are highly specific to endothelial cells. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that VEGI functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature. GenScript, Vascular Endothelial Growth Inhibitor (VEGI), human , produced in, E. coli , is a single, non-glycosylated polypeptide chain containing 192 amino acids and having a molecular mass of 21,858 Da.</td></tr><tr><th>M.W.</th><td colspan="7"> 21,858 Da</td></tr><tr><th>Purity</th><td colspan="7"> The purity of GenScript Recombinant Human VEGI-192 is greater than 95.0%, as determined by the following methods: (a) RP-HPLC analysis (b) Reducing and non-reducing SDS-PAGE silver-stained gel analysis</td></tr><tr><th>Endotoxin Level</th><td colspan="7"> The endotoxin level of GenScript Recombinant Human VEGI-192 is below 0.1 ng/ug (1 IEU/ug) of rHuVEGI.</td></tr><tr><th>Storage</th><td colspan="7"> Although lyophilized VEGI-192 can remain stable at room temperature for up to three weeks, it is best stored desiccated below -18C. After reconstitution, VEGI-192 may be stored at 4C for up to seven days and below -18C for longer periods. For long-term storage, it is recommended that a carrier protein (0.1% HSA or BSA) be added. Please avoid freeze-thaw cycles.</td></tr><tr><th>Specificity</th><td colspan="7"> The ED50, as determined by the dose-dependant inhibition of the proliferation of HUVEC (Human Umbilical Vein Endothelial Cells), is less than 5 ug/ml.</td></tr><tr><th>Formulation</th><td colspan="7"> GenScript Recombinant Human VEGI-192 is lyophilized after extensive dialysis against 0.5 M NaCl, 50 mM Tris-HCl buffer, pH 7.5.</td></tr><tr><th>Reconstitution</th><td colspan="7"> It is recommended, that the lyophilized VEGI-192 be reconstituted in sterile 18 M&
Similar products Vascular
Available
Specificity The ED50, as determined by the dose-dependant inhibition of the proliferation of HUVEC (Human Umbilical Vein Endothelial Cells), is less than 5 ug/ml.
Country of Origin
USA
Storage Conditions
Although lyophilized VEGI-192 can remain stable at room temperature for up to three weeks, it is best stored desiccated below -18C. After reconstitution, VEGI-192 may be stored at 4C for up to seven days and below -18C for longer periods. For long-term storage, it is recommended that a carrier protein (0.1% HSA or BSA) be added. Please avoid freeze-thaw cycles.
Molecular Weight
21, 858 Da
Product Line
Cytokine, Chemokines & Growth Factors
Manufacturer - Specificity
The ED50, as determined by the dose-dependant inhibition of the proliferation of HUVEC (Human Umbilical Vein Endothelial Cells), is less than 5 ug/ml.
Description
Vascular endothelial growth inhibitor (VEGI, TNFSF-15) is a new member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli, and programmed death of proliferating cells. These activities are highly specific to endothelial cells. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that VEGI functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature. GenScript, Vascular Endothelial Growth Inhibitor (VEGI), human , produced in, E. coli , is a single, non-glycosylated polypeptide chain containing 192 amino acids and having a molecular mass of 21, 858 Da.
Reconstitution
It is recommended, that the lyophilized VEGI-192 be reconstituted in sterile 18 MΩ, -cm H2O not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.
Formulation
GenScript Recombinant Human VEGI-192 is lyophilized after extensive dialysis against 0.5 M NaCl, 50 mM Tris-HCl buffer, pH 7.5.
Endotoxin Level
The endotoxin level of GenScript Recombinant Human VEGI-192 is below 0.1 ng/ug (1 IEU/ug) of rHuVEGI.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close